Denali Therapeutics Inc. (DNLI) Financial Statements (2026 and earlier)

Company Profile

Business Address 161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments832,3311,034,5111,336,215865,4071,469,697415,356
Cash and cash equivalent174,960127,106218,044293,477507,14479,449
Short-term investments657,371907,4051,118,171571,930962,553335,907
Receivables    1,2265,674 
Other undisclosed current assets32,10529,62636,10430,60120,28414,675
Total current assets:864,4361,064,1371,372,319897,2341,495,655430,031
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization47,533     
Operating lease, right-of-use asset22,86126,04830,43730,74332,61833,923
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization55,23645,58944,08738,86540,84646,732
Long-term investments and receivables359,373  425,44932,69939,886
Long-term investments359,373  425,44932,69939,886
Other noncurrent assets24,74118,14313,39911,8712,4622,659
Total noncurrent assets:509,74489,78087,923506,928108,625123,200
TOTAL ASSETS:1,374,1801,153,9171,460,2421,404,1621,604,280553,231
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities102,20877,9822,7904,7791,0712,590
Accounts payable11,1379,4832,7904,7791,0712,590
Accrued liabilities91,07168,499    
Deferred revenue    27,91519,91418,739
Other liabilities   66,69153,16547,14524,015
Due to related parties4,388   
Other undisclosed current liabilities   290,053292,3863,569 
Total current liabilities:102,20877,982363,922378,24571,69945,344
Noncurrent Liabilities
Long-term debt and lease obligation5,615  58,55464,17568,865
Finance lease, liability5,615     
Liabilities, other than long-term debt36,67344,98153,4113,77724,02644,132
Deferred revenue    3,39823,32543,753
Other liabilities   379379701379
Operating lease, liability36,67344,98153,03258,55464,17568,865
Other undisclosed noncurrent liabilities   4791,295293,849 
Total noncurrent liabilities:42,28844,98153,89063,626382,050112,997
Total liabilities:144,496122,963417,812441,871453,749158,341
Equity
Equity, attributable to parent, including:1,229,6841,030,9541,042,430962,2911,150,531394,890
Common stock  1,7111,6861,5481,5311,288
Additional paid in capital2,764,8802,144,8112,018,6171,608,2381,503,660818,803
Accumulated other comprehensive income (loss)2,020643(6,886)(2,499)(245)350
Accumulated deficit(1,538,984)(1,116,211)(970,987)(644,996)(354,415)(425,551)
Other undisclosed equity, attributable to parent1,768     
Total equity:1,229,6841,030,9541,042,430962,2911,150,531394,890
TOTAL LIABILITIES AND EQUITY:1,374,1801,153,9171,460,2421,404,1621,604,280553,231

Income Statement (P&L) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues  330,531108,46348,661335,65926,678
Revenue from related parties3,2003,736307,437 
Gross profit:  330,531108,46348,661335,65926,678
Operating expenses(501,878)(527,230)(449,207)(344,412)(272,941)(239,862)
Other undisclosed operating income 14,537     
Operating income (loss):(487,341)(196,699)(340,744)(295,751)62,718(213,184)
Nonoperating income  51,50514,7744,5959,24115,219
Investment income, nonoperating  43,9521,637(8,748)(55)5,019
Interest and debt expense(300)     
Income (loss) from continuing operations before income taxes:(487,641)(145,194)(325,970)(291,156)71,959(197,965)
Income tax expense (benefit)(68)(30)(21)575823351
Income (loss) from continuing operations:(487,709)(145,224)(325,991)(290,581)72,782(197,614)
Income (loss) before gain (loss) on sale of properties:(290,581)72,782(197,614)
Net income (loss):(487,709)(145,224)(325,991)(290,581)72,782(197,614)
Other undisclosed net income (loss) attributable to parent64,936   (1,646) 
Net income (loss) available to common stockholders, diluted:(422,773)(145,224)(325,991)(290,581)71,136(197,614)

Comprehensive Income ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(487,709)(145,224)(325,991)(290,581)72,782(197,614)
Comprehensive income (loss):(487,709)(145,224)(325,991)(290,581)72,782(197,614)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent66,3137,529(4,387)(2,254)(2,241)999
Comprehensive income (loss), net of tax, attributable to parent:(421,396)(137,695)(330,378)(292,835)70,541(196,615)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: